ASCO publishes a suite of peer-reviewed journals with content focused on
- clinical oncology research;
- issues and insights affecting oncology practice;
- cancer care, research and care delivery issues unique to countries and settings with limited healthcare resources;
- biomedical informatics methods and processes applied to cancer-related data, information, and images; and
- the science and practice of precision oncology.
ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author.
ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.
Embargoed until March 29, 4:00 pm ET:
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study (JCO: Original Report)
Giovanni Martinelli, et al.
Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial (JCO: Original Report)
Stefano Arcangeli, et al.
(Editorial by James Yu, et al.)
Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma (JCO: Original Report)
Andreas Ranft, et al.
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy (JCO: Original Report)
Emanuele Zucca, et al.
Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales (JCO: Editorial)
James Yu, et al.
(Accompanies Stefano Arcangeli, et al.)
Unexpected CDH1 Mutations Identified on Multigene Panels Pose Clinical Management Challenges (JCO PO: Original Report)
Duveen Sturgeon, et al.
(Editorial by James Ford, et al.)
Totally Unexpected: Nonsyndromic CDH1Mutations and Hereditary Diffuse Gastric Cancer Syndrome (JCO PO: Editorial)
James Ford, et al.
(Accompanies Duveen Sturgeon, et al.)
Embargoed until March 28, 4:00 pm ET:
Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model (JCO: Original Report)
Firas Abdollah, et al.
Reproductive Patterns Among Childhood and Adolescent Cancer Survivors in Sweden: A Population-Based Matched-Cohort Study (JCO: Original Report)
Gabriela Armuand, et al.
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis) (JCO: Original Report)
Shivaani Kummar, et al.
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents (JCO: Original Report)
Sophie Park, et al.
Survival Disparities by Hospital Volume Among American Women With Gynecologic Cancers (JCO CCI: Original Report)
Brandon-Luke Seagle, et al.
Reporting Margin Status in Synoptic Reports (JCO CCI: Original Report)
Andrew Renshaw, et al.
Data-Derived Treatment Duration Goal for Cervical Cancer: Should 8 Weeks Remain the Target in the Era of Concurrent Chemoradiation? (JCO CCI: Original Report)
Julian Hong, et al.
Embargoed until March 25, 4:00 pm ET:
Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update (JCO: ASCO Special Article)
R. Bryan Rumble, et al.
Active Surveillance in Younger Men With Prostate Cancer (JCO: Original Report)
Michael Leapman, et al.
(Editorial by Mark Garzotto, et al.)
Patient-Reported Outcomes 1 Year After Immediate Breast Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study (JCO: Original Report)
Andrea Pusic, et al.
Is Low-Risk Prostate Cancer More Indolent in Younger Patients? (JCO: Editorial)
Mark Garzotto, et al.
(Accompanies Michael Leapman, et al.)
Breast Cancer in Ghana: Demonstrating the Need for Population-Based Cancer Registries in Low- and Middle-Income Countries (JGO: Original Report)
Abigail Thomas, et al.
Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer (JGO: Original Report)
Manuel Maia, et al.
Pilot Educational Intervention and Feasibility Assessment of Breast Ultrasound in Rural South Africa (JGO: Original Report)
Susan Harvey, et al.
Breast Cancer in Sub-Saharan Africa (JGO: Editorial)
Edward Trimble, et al.
Embargoed until March 24, 4:00 pm ET:
Morbidity and Mortality Associated With Meningioma After Cranial Radiotherapy: A Report From the Childhood Cancer Survivor Study (JCO: Original Report)
Daniel Bowers, et al.
Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group Study AALL03N1 (JCO: Original Report)
Smita Bhatia, et al.
Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources (JGO: Original Report)
Michael Bishop, et al.
Variation in Adherence Measures to Imatinib Therapy (JGO: Original Report)
Pankaj Malhotra, et al.
Embargoed until March 22, 4:00 pm ET:
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study (JCO: Original Report)
Joshua Bauml, et al.
The State of Cancer Care in America, 2017: A Report by the American Society of Clinical Oncology (JOP: ASCO Special Article)
M. Kirkwood, et al.
(Special Posting Notice: Embargoed until Wednesday, March 22, at 8:00 am ET).
Embargoed until March 21, 4:00 pm ET:
Long and Winding Road of Cancer and Pregnancy: A Need for Action (JCO: Editorial)
Fedro Peccatori, et al.
Barriers to Scale of Digital Health Systems for Cancer Care and Control in Last-Mile Settings (JGO: Special Article)
Jay Evans, et al.
The embargo date and time of a journal article coincides with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year, and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.